Nogapendekin
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 34 publications
Cost-per-responder analysis of TAR-200 versus other Food and Drug Administration-approved novel and generic treatments among patients with Bacillus Calmette-Guérin-unresponsive, high-risk, non-muscle-invasive bladder cancer with carcinoma in situ in the United States.
Journal: Journal of medical economics
Published: April 21, 2026
Budget impact model of nadofaragene firadenovec for the treatment of high-risk non-muscle-invasive bladder cancer that is unresponsive to Bacillus Calmette-Guérin immunotherapy.
Journal: Journal of medical economics
Published: March 04, 2026
Design and preliminary report of a randomized phase IIb clinical trial of multitargeted recombinant adenovirus 5 vaccines against CEA, MUC1, and brachyury (Tri-Ad5) and the IL-15 receptor superagonist nogapendekin alfa inbakicept in Lynch syndrome (TRIAD5-Plus): the first cross-network trial of the Cancer Prevention Clinical Trials Network (CP-CTNet).
Journal: Frontiers in immunology
Published: February 11, 2026
Advances in IL-15-Based Cancer Immunotherapy and Divergent Immunological Effects of IL-2 and IL-15 Signaling via the Shared IL-2Rβγ Receptor.
Journal: Frontiers in immunology
Published: January 19, 2026
Recent Advances in Immunotherapy for Non-Muscle-Invasive Bladder Cancer.
Journal: Cancers
Published: December 31, 2025
Decoding Immune Mechanisms in BCG-unresponsive Non-muscle Invasive Bladder Cancer.
Journal: Frontiers in bioscience (Landmark edition)
Published: October 23, 2025
Intravesical gemcitabine (Inlexzo) for bladder cancer.
Journal: The Medical letter on drugs and therapeutics
Published: October 21, 2025
A national perspective on the management of high-risk BCG-unresponsive non-muscle-invasive bladder cancer in Romania.
Journal: Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
Published: October 20, 2025
Male reproductive and sexual health outcomes following intravesical therapy for non-muscle invasive bladder cancer.
Journal: World journal of urology
Published: October 08, 2025
Prolonged Progression-Free Survival, Disease-Free Survival, and Cystectomy Avoidance With IL-15 Receptor Lymphocyte-Stimulating Agent NAI Plus Bacillus Calmette-Guérin in Bacillus Calmette-Guérin-Unresponsive Papillary-Only Nonmuscle-Invasive Bladder Cancer.
Journal: The Journal of urology
Published: September 16, 2025
The ATR inhibitor tuvusertib (M1774) sensitizes prostate carcinoma to natural killer cell-mediated cytotoxicity, which is further augmented by the IL-15 receptor superagonist N-803.
Journal: Cancer immunology, immunotherapy : CII
Published: August 26, 2025
Traditional and next-generation bacillus Calmette-Guérin based treatment strategies for bacillus Calmette-Guérin unresponsive non-muscle-invasive bladder cancer in the era of emerging therapies.
Journal: Current opinion in urology
Published: July 14, 2025
Last Updated: 06/30/2026